Predictive Oncology Inc Stock Price, News & Analysis

Predictive Oncology (NASDAQ: POAI) announces that its chief innovation officer, Mark Collins, Ph.D., recently spoke on DojoLIVE!, discussing the potential of AI in cancer treatment. Helomics, a subsidiary, utilizes its Tumor Drug Response Profiling (TDRP) platform, which has generated profiles from over 150,000 tumors, aiming to personalize cancer therapies and collaborate with pharma on new therapies. The company also operates TumorGenesis and Skyline Medical. It's important to note the inherent risks in forward-looking statements as they may vary from actual results.

Predictive Oncology (NASDAQ: POAI) reported Q2 2020 financial results, highlighting a revenue of $183,000, down from $286,000 year-over-year. The company achieved its first commercial sale of ovarian cancer cell media and completed acquisitions of Soluble Therapeutics and BioDtech, enhancing its capabilities in precision medicine. The net loss was $3.6 million, with improvements in operational expenses. Management is optimistic about ongoing Helomics and TumorGenesis initiatives while raising $4.6 million through equity offerings to strengthen liquidity.

Predictive Oncology (NASDAQ: POAI) released a letter to shareholders highlighting key business achievements and proposals for a vote on September 3, 2020. Significant accomplishments include the acquisition of Quantitative Medicine, enhancing AI-driven drug discovery, and the first commercial sale of ovarian cancer media. The company also aims to reprice stock options and increase its share reserve to attract talent. Recent financial improvements encompass a $4.4 million capital raise and restructuring of debt, aimed at positioning the company for future growth and enhancing shareholder value.

Predictive Oncology (NASDAQ: POAI) has acquired Quantitative Medicine LLC in an all-stock deal valued at approximately $1.8 million. This acquisition integrates QM's CoRE™ drug discovery platform, aimed at enhancing Predictive Oncology's capabilities in personalized medicine and drug development. Leveraging a database from over 150,000 cancer cases, the combined efforts are expected to accelerate the development of new anti-cancer therapeutics and improve patient outcomes. The acquisition is also anticipated to generate revenue from future pharmaceutical collaborations.

Predictive Oncology Inc. (NASDAQ: POAI) announced the successful closure of a transaction leading to gross cash proceeds of approximately $2.2 million from warrant exercises. The transaction involved the exercise of 1,396,826 shares at $1.575 per share, offering new unregistered warrants at $1.80 per share valid for five and a half years. The funds will be utilized for working capital and general corporate purposes. H.C. Wainwright & Co. acted as the exclusive placement agent. The new warrants and shares will not be registered under the Securities Act, available only to accredited investors.

Predictive Oncology (NASDAQ: POAI) has made significant strides by fulfilling its first commercial order for specialized ovarian cancer cell culture media. This media, developed by its TumorGenesis division, allows researchers to grow patient-derived ovarian cancer cells more effectively, preserving crucial DNA, RNA, and proteomic signatures. The order was placed by a leading medical institution in New England. This innovative product aims to address the challenges posed by unvalidated media that increases research costs and reproducibility issues, ultimately driving advancements in cancer treatment research.

Predictive Oncology (NASDAQ: POAI) reported Q1 2020 revenues of $295,943, up from $255,241 year-over-year, driven primarily by STREAMWAY unit sales. Gross margins remained strong at 69%. However, net loss increased to $4.5 million from $3.3 million in the same quarter last year. The company is actively pursuing potential acquisitions to bolster its capabilities, including a COVID-19 vaccine development. The operational focus remains on the Helomics and TumorGenesis divisions, emphasizing AI applications in precision medicine.

Predictive Oncology (NASDAQ: POAI) has acquired the assets of Soluble Therapeutics and BioDtech, both subsidiaries of InventaBioTech, for 125,000 shares of common stock, alongside waiving a $1.07 million promissory note. This acquisition enhances Predictive's capabilities in precision medicine and drug formulation. CEO Dr. Carl Schwartz highlighted that the Soluble assets improve service offerings to pharmaceutical and biotech industries, while BioDtech's test allows monitoring of endotoxins, optimizing treatment strategies. These moves aim to bolster revenue prospects and expand the company’s market presence.

Predictive Oncology (NASDAQ: POAI) announced a registered direct offering of 1,396,826 shares of common stock at $1.575 per share, raising approximately $2.2 million. The offering includes unregistered warrants for the same number of shares, exercisable at $1.45 each for five and a half years. The company plans to use $487,000 of the net proceeds to repay debt and the remainder for working capital. The offering is expected to close on May 8, 2020, subject to customary conditions. H.C. Wainwright & Co. is the exclusive placement agent for this transaction.